Extracorporeal Cytokine Removal in Critically Ill COVID-19 Patients: A Case Series

Marcell Virág 1,2,3, Máté Rottler 1,2,3, Klementina Ocskay 1, Tamás Leiner 1,4, Balázs Horváth 1, Daniel Adam Blanco 5, Alexa Vasquez 5, László Bucsi 6, Ágnes Sárkány 2 and Zsolt Molnár 1,3,5,7,8*

1 Medical School, Institute for Translational Medicine, University of Pécs, Pécs, Hungary, 2 Department of Anesthesiology and Intensive Therapy, Szent György University Teaching Hospital of Fejér County, Székesfehérvár, Hungary, 3 Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary, 4 Anaesthetic Department, Hinchingbrooke Hospital, North West Anglia National Health Service (NHS) Foundation Trust, Huntingdon, United Kingdom, 5 CytoSorbents Europe, Berlin, Germany, 6 Szent György University Teaching Hospital of Fejér County, Székesfehérvár, Hungary, 7 Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland, 8 Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary

Introduction: Extracorporeal hemoadsorption (HA) is a potential adjunctive therapy in severe cases of COVID-19 associated pneumonia. In this retrospective study we report data from critically ill patients treated with HA during the first and second wave of the pandemic.

Patients and Methods: All patients, who received HA therapy with CytoSorb within the first 96 h of intensive care unit (ICU) admission without hospital-acquired bacterial superinfection, were included. Clinical and laboratory data were collected: on admission, before (T_B) and after (T_A) HA therapy.

Results: Out of the 367 COVID-19 cases, 13 patients were treated with CytoSorb, also requiring mechanical ventilation and renal replacement therapy. All patients were alive at the end of HA, but only 3 survived hospital stay. From T_B - T_A there was a tendency of decreasing norepinephrine requirement: 193.7 [IQR: 34.8–270.4] to 50.2 [6.5–243.5] ug/kg/day and increasing PaO2/FiO2 ratio 127.8 (95% CI: 96.0–159.6) to 155.0 (115.3–194.6) mmHg but they did not reach statistical significance (p = 0.14 and 0.58, respectively). Treatment related adverse events were not reported.

Conclusion: The treatment was well-tolerated, and there was a tendency toward an improvement in vasopressor need and oxygenation during the course of HA. These observations render the need for prospective randomized trials.

Keywords: ARDS, cytokine storm, CRRT, COVID-19, hemoadsorption, CytoSorb

INTRODUCTION

Treating critically ill Coronavirus Disease 19 (COVID-19) patients has become the most significant challenge intensive care has ever faced. The vast number of patients requiring care simultaneously, and the novelty and unpredictability of the virus created unprecedented environment for all involved. Hospitals were overwhelmed by the continuous influx of severely unwell patients, and
intensive care units (ICUs) expanded beyond their original footprint. Critical care mortality of COVID-19 patients significantly exceeded the mortality of any other viral pneumonia (37.9 vs. 22.0%) (1).

Due to the early introduction of lockdown during the first wave of the pandemic, Hungary experienced significantly less pressure on its healthcare system compared to most of the Western European countries. However, it was hit very hard by the next consecutive waves during the autumn and winter of 2020–2021, which resulted in one of the, if not the highest rates of COVID-19 mortality per capita in the world (304.33 deaths/100,000) (2).

Early reports of observations indicated that cytokines might play a considerable role in the development of severe COVID-19. Patients who required critical care admission had higher levels of cytokines. Furthermore, tumour necrosis factor-alfa (TNFa) levels correlated with disease severity, and high interleukin 6 (IL-6), C-reactive protein (CRP), D-Dimer and ferritin levels were found to be predictors of mortality (3–5).

There is some evidence that with extracorporeal cytokine adsorption, substantial IL-6 removal is achievable in severely ill patients with septic shock, acute respiratory distress syndrome (ARDS), and multi-organ failure (6). In a Hungarian proof of concept randomised, controlled pilot study, a significant reduction in vasopressor need and serum procalcitonin levels were found (7). Moreover, in a retrospective study of patients with septic shock, cytokine removal was associated with a decreased observed vs. expected 28-day all-cause mortality (8).

In our tertiary intensive care unit (ICU) we have also used hemoadsorption (HA) as an adjuvant therapy in selected patients with septic shock, acute respiratory distress syndrome (ARDS), and multi-organ failure (6). In a Hungarian proof of concept randomised, controlled pilot study, a significant reduction in vasopressor need and serum procalcitonin levels were found (7). Moreover, in a retrospective study of patients with septic shock, cytokine removal was associated with a decreased observed vs. expected 28-day all-cause mortality (8).

The aim of the current retrospective study is to summarise our experience with extracorporeal cytokine adsorption in critically ill COVID-19 patients admitted to our ICU during the first and second wave of the pandemic.

**PATIENTS AND METHODS**

For this retrospective case-series we screened the records of all patients admitted to the ICU of the Department of Anaesthesia and Intensive Care Medicine at Fejér County St. György University Teaching Hospital, Székesfehérvár, Hungary, between March 1st 2020 and January 31st, 2021. Approval from the local ethics committee was obtained (No: 18/2021.05.11.). Due to the retrospective and anonymized data collection process, patients' informed consent was not deemed necessary.

We identified patients, who had severe, life-threatening COVID-19 confirmed with either polymerase chain reaction (PCR) or rapid antigen testing.

All patients had severe respiratory failure requiring mechanical ventilation and received standard intensive monitoring and therapy based on international guidelines and recommendations.

All patients, who received HA therapy within the first 96h of ICU admission were considered eligible for the analysis. Hemadsorption treatment was applied as an additional adsorbent cartridge (CytoSorb/CytoSorbents Europe GmbH, Berlin, Germany) integrated into a continuous renal replacement (CRRT) circuit. Patients who received HA more, than up to a maximum of 96h after ICU admission were presumed to have septic shock due to hospital acquired secondary infections, hence they were excluded. Those, who died within 48h of the application of the first HA were excluded.

The indication to start CRRT was based on our local protocol: CRRT was commenced in patients with acute renal injury (AKI) stage II according to Kidney Disease Improving Global Outcomes (KDIGO) criteria or severe refractory fluid overload, furthermore in patients without renal indication in order to facilitate HA therapy in hemoperfusion mode only (9).

Executing CRRT with or without HA was at the discretion of the attending senior intensive care physician. Nevertheless, by-and-large the following indications were taken into account: suspicion of hyper-inflammatory state based on elevated inflammatory markers such as CRP and granulocyte count combined with considerable hemodynamic instability necessitating increasing doses of catecholamines and/or severe ARDS defined by the Berlin definition and/or multiple organ failure (10).

Integration of the adsorber into the CRRT circuit (Prismaflex System/Baxter International Inc., Deerfield, IL, USA) was handled by trained intensive care physicians following the manufacturer's instructions. The cartridge was placed in pre-dialyzer position. CRRT was performed in continuous hemodiafiltration mode (CVVHDF), as our standard practise, at a blood flow rate of 100–250 ml/min with systemic unfractionated heparin or regional citrate anticoagulant as recommended by the KDIGO 2012 recommendations (11).

Based on the attending physician's decision the cartridges were changed every 12 or 24h. According to our standard operating procedures, hemoadsorption was discontinued in cases of clinical improvement as indicated by a reduction in the required catecholamine dose, increase in the PaO2/FiO2 ratio, or due to deterioration in the patient's overall condition or no improvement after 2 treatment sessions.

Data collection was undertaken retrospectively by review of our electronic medical records. We gathered pertinent information on demographic data and past medical history. For risk stratification the 4C and sequential organ failure assessment scores (SOFA) were calculated. Relevant clinical data were assessed at three different time points: (1) on admission, (2) at the onset of the adsorbent therapy (“before,” TB), and 3) after the completion of adsorbent therapy (“after,” TA). We measured inflammatory markers such as leukocyte and granulocyte count, CRP, procalcitonin (PCT), hemodynamic parameters such as catecholamine requirement, serum lactate levels; respiratory function as indicated by the PaO2/FiO2 ratio, PaCO2, and
renal function assessed by blood urea nitrogen, creatinine and glomerular filtration rate. We analysed the association between the use of HA and changes in SOFA-score, in the PaO2/FiO2 ratio and in catecholamine dose, as well as days on mechanical ventilation, ICU length-of-stay and 28-day mortality.

Statistical Analysis
Data were collected in a preformatted, anonymized table, which had been used exclusively for all further analyses. All calculations were undertaken by means of descriptive statistics. Continuous variables were expressed as mean (confidence interval, CI) or median [interquartile range, IQR], as appropriate. Statistical analyses and graphs were performed with STATA 15 software using parametric and non-parametric methods for mean and median comparisons as appropriate.

RESULTS
Baseline Characteristics
Out of the 367 patients treated with COVID-19 in the ICU, invasive ventilation was necessary in 153 cases. Thirty-Seven patients were on CRRT, and 13 patients were included the current case series suffering from COVID-19 viral pneumonia, who received hemoadsorption therapy with CytoSorb. Three patients were admitted to our ICU after CRRT and one patient was transferred from another hospital's ICU. All four patients were admitted to our ICU within 24 h after the onset of symptoms, hence hospital acquired infection was highly unlikely.

Baseline characteristics, comorbidities and on-admission laboratory values of the included patients are presented in Table 1. All patients but one were male, with a mean age of 57 (±11) years. According to the 4C prognostic mortality score most patients (61.6%) had at high or very high risk on admission. Nine patients (69.2%) suffered from some sort of comorbidity, including hypertension, diabetes, or acute myocardial infarction. Regarding on-admission laboratory parameters, as indicated by the average values, granulocyte/lymphocyte ratio, CRP, lactate dehydrogenase, creatinine kinase, glutamic oxaloacetic transaminase, and gamma-glutamyl transferase, were elevated. The applied antiviral and adjunctive therapies are detailed in Table 1.

The mean time between the onset of symptoms and admission to the Emergency Department was 5.9 (95% CI: 4.11–7.55) days. The diagnosis of SARS-CoV2 infection was confirmed by PCR in ten and antigen testing in three cases. Two patients had chest computer tomography and eleven X-Ray, and except for one patient, bilateral pathology was observed. Nine patients were admitted from the Emergency Department to the ICU on the day of admission, three were transferred from the COVID-Internal Medicine and one from the ICU on the day of admission, three were transferred from the department of COVID-Internal Medicine and one from the ICU of another town.

Treatment Characteristics
In all cases, hemoadsorption was combined with CRRT. On average 1.6 days elapsed from admission to the application of the first adsorber. Regarding the number of treatments, 1 patient received only one treatment, 5 received two, 6 received three treatments and in 1 case hemoadsorption was repeated for four consecutive sessions.

All patients required mechanical ventilation due to acute hypoxemic respiratory failure. Vasopressor was also required in all patients. In the first 24 h the total dose of norepinephrine was

| TABLE 1 | Baseline characteristics. | Patients (n = 13) |
| --- | --- | --- |
| Age, years | 62 [48–67] | |
| Male | 12 (92.3%) | |
| Charlson comorbidity index | 2.77 [1.1–4.4] | |
| 4C Mortality score for COVID-19 | 10.4 [7.6–13.2] | |
| Low risk | 1 (7.7%) | |
| Intermediate risk | 4 (30.8%) | |
| High risk | 5 (38.5%) | |
| Very high risk | 3 (23.1%) | |
| Onset of symptoms before admission, days | 5.8 [3.8–7.8] | |
| Confirmed by COVID-19 antigen test | 3 (23.1%) | |
| Confirmed by PCR | 10 (76.9%) | |
| Comorbidities | 9 (69.2%) | |
| Hypertension | 6 (46.2%) | |
| Diabetes | 1 (7.7%) | |
| Gastroesophageal reflux disease | 2 (15.4%) | |
| Acute myocardial infarction | 2 (15.4%) | |
| Benign prostatic hyperplasia | 6 (46.2%) | |
| Other | 4 (30.8%) | |
| Laboratory values on admission | 9 (69.2%) | |
| Leukocytes, × 10^9/µL | 8.9 [6.6–11.2] | |
| Lymphocytes, × 10^9/µL | 0.7 [0.58–1.04] | |
| Granulocytes, × 10^9/µL | 7.4 [5.3–9.6] | |
| Granulocyte/lymphocyte ratio | 10.0 [6.9–13.1] | |
| C-reactive protein, mg/L | 203 [116–290] | |
| Glutamic oxaloacetic transaminase, U/L | 96 [42–113] | |
| Glutamate pyruvate transaminase, U/L | 75 [40–109] | |
| Gamma-glutamyl transferase, U/L | 131.1 [66.3–195.9] | |
| Alkaline phosphatase, U/L | 100.1 [68.3–131.9] | |
| Lactate dehydrogenase, U/L | 1,164.8 [780.9–1,548.8] | |
| Blood urea nitrogen, mmol/L | 6.4 [4.8–13.3] | |
| Creatine kinase, U/L | 160 [126–489] | |
| Initial antiviral therapy | 11 (84.6%) | |
| Oseltamivir | 4 (30.8%) | |
| Favipiravir | 6 (46.2%) | |
| Lopinavir | 1 (7.7%) | |
| Adjunctive therapy | 5 (38.5%) | |
| Dexamethasone | 2 (15.4%) | |
| Hydrocortisone | 4 (30.8%) | |
| Methyl-prednisolone | 4 (30.8%) | |
| Tocilizumab | 4 (30.8%) | |
| Anti-COVId-19 convalescent plasma | 5 (38.5%) | |

Data are presented as mean (95% CI), median [IQR], or n (%), unless otherwise specified. PCR, polymerase chain reaction. U/L, unit/litre; ICU, intensive care unit. *represents elevated values.
193.7 ug/kg/day [34.8–270.4] which decreased to 50.2 [6.5–243.5] ug/kg/day, by the end of the course of hemoadsorption, but did not reach statistical significance (Figure 1A). There was a similar tendency of an improvement in the PaO2/FiO2 ratio during the course of hemoadsorption from 127.8 (96.0–159.6) to 155.0 (115.3–194.6) mmHg (Figure 1B). Apart from the leukocyte count, all other recorded laboratory parameters and the SOFA score showed statistically non-significant changes from before to after the therapy (Table 2).

Fluid management and inotropic support are summarised in Table 3. The only significant change was a negative fluid balance (TB vs. TA) on the completion of hemoadsorption compared to the onset of implication of the first HA.

**Overall Outcomes**

All patients survived the course of hemoadsorption and were still alive 72 h after initiation of the treatment, hence therapy was not terminated due to deterioration and also no adverse
**TABLE 3** | Summary of daily changes in fluid balance and inotropic support requirement.

| Fluid balance | TB | TA | p-value |
|---------------|----|----|---------|
| Intake fluids per orally, ml | 335 [141–529] | 554 [150–958] | 0.24 |
| Intake fluids intravenously, ml | 3,760 [3143–4377] | 3,386 [2875–3897] | 0.31 |
| Spontaneous urinary output, ml | 1,600 [750–2,300] | 1,200 [0–3,850] | 0.32 |
| Other fluid loss, ml | 200 [0–400] | 0 [0–200] | 0.24 |
| Remove by continuous renal replacement, ml | 0 [0–300] | 953 [300–2,400] | 0.20 |
| Daily fluid balance, ml | 1,947 [1,053–2,840] | −322 [−1,388–745] | <0.01 |
| Vasopressor requirement | |
| Norepinephrine, µg/kg/day | 193.7 [34.8–270.4] | 50.2 [6.5–243.5] | 0.48 |
| Dobutamine, µg/kg/day | 0.0 [0.0–1,005.7] | 0.0 [0.0–6,437.5] | 0.03 |

Data are expressed as mean (95% CI) or median [IQR], unless otherwise specified. HA, haemoadsorption.

**DISCUSSION**

To the best of our knowledge, this is the first and largest comprehensive case series on COVID-19 patients treated with hemoadsorption from Eastern Europe—i.e.: from the former socialist block. Although the results showed some improvement in both haemodynamics and oxygenation, likely due to small sample size statistical significance was not achieved. Nevertheless, all patients were alive when treatment was decided to be terminated by the attending medical team, and treatment-related adverse events were not re-reported. Death occurred due to multiple organ failure at least 2 weeks later in most cases, suggesting that hemoadsorption started within 96 h after admission to ICU was well-tolerated and helped to stabilise and overcome the initial critical phase.

The purpose of hemoadsorption in the critically ill in general is to remove excessive inflammatory mediators and by doing so, to attenuate the host immune response. Whether a dysregulated immune response is present or not in COVID-19 patients at all, hence whether hemoadsorption is indicated or not, remains a controversial topic despite extensive publications in the field over the last year. There are several reports indicating elevated cytokine levels in the critically ill forms of COVID-19, some even observed the presence of cytokine storm (12, 13). However, there are also reports contradicting this hypothesis (14, 15). Nevertheless, as the clinical phenotype of COVID-19 is highly variable, ranging from asymptomatic cases to multi organ failure, one would expect a similar variability for the immune response (16). In recent correspondence by Rieder et al. on 8 patients with severe COVID-19 requiring veno-venous-extracorporeal membrane oxygenation (the CYCOV study), patients who received extracorporeal cytokine adsorption had lower IL-6 levels after 72 h of treatment compared to patients without cytokine adsorption (17). However, after completion of the study the difference was not significant (18).

In our patients there are some signals of increased inflammatory activity as indicated by the elevated granulocyte/lymphocyte ratio, and CRP and PCT levels, but these are certainly less pronounced as seen in septic shock or severe ARDS (14). Regardless of the measured inflammatory biomarker levels, the clinical picture of hemodynamic instability requiring vasopressor support, severe ARDS and renal failure indicates the presence of a dysregulated immune response of some sort. Therefore, which biomarkers are the most appropriate to be measured in COVID-19 patients remains to be elucidated (19).

Regarding the clinical effects of hemoadsorption with CytoSorb, there are several, consistent reports of hemodynamic stabilisation before and after the therapy from several fields of critical care including cardiac surgery, septic shock and also recent reports in COVID-19 patients (7, 20, 21). However, the amount of published data on hemoadsorption in COVID-19 patients remains very limited. The largest patient cohort on COVID-19 patients treated with hemoadsorption to date, was published by Alharthy et al. (22). Fifty patients with life threatening COVID-19 and acute kidney injury were treated with CytoSorb. Before and after treatment laboratory and clinical values were compared in the 35 survivors to 15 non-survivors. Most organ functions, including vasopressor need, PaO2/FiO2, and inflammatory biomarker levels improved significantly amongst survivors, while al-most all of these events were detected. Four patients survived 28-days, but overall, only 3 patients (23.1%) were discharged from the hospital alive. ICU length of stay was 14 [5–30] days while patients spent a median 17 [6–30] days in the hospital in total.
deteriorated in non-survivors. Due to the limited number of patients we could not compare the 10 non-survivors to the 3 survivors in our study. Nevertheless, the tendency was also similar in our cases, although the improvement did not reach statistical significance. This can be explained on the one hand by the small sample size, on the other hand there is some data suggesting the starting HA within 24 h as compared to the average 1.6 days found in our study, could have more profound effects (23).

Our patient cohort is similar to that presented in previous studies, as far as age, comorbidities and treatment modalities are concerned. However, the observed mortality was substantially higher (77%) than in other studies (22, 24, 25), apart from one recent randomised trial in patients requiring extracorporeal membrane oxygenation (ECMO) due to COVID-19 caused respiratory failure (18). In this study, Supady et al. (18) report a striking difference in 28-day survival of 18% in the cytokine adsorption treated vs. 76% in the controls. However, this was a small (17 vs. 17 patients) single centre study. There were also some baseline differences between the groups as far as baseline norepinephrine requirement, D-Dimer levels, and fluid balance were concerned, hence firm conclusions from this study cannot be drawn at present. Finally, this trial included patients on ECMO, which is different from our patient cohort. One most note, that the average 4C mortality score was 10.4, which indicates high risk and corresponds to 31.4–34.9% in-hospital mortality. Five patients were in the high risk and three in the very high risk category. However, these patients all required mechanical ventilation, therefore were of a selected subpopulation with even more severe conditions (26).

However, an important fact is that mortality rate during the 2nd and especially during the 3rd wave of COVID-19 was a lot higher in Eastern Europe in general than in Western Europe or in the United States (27–30). Unfortunately, we do not have detailed data on ICU/mechanical ventilation specific outcomes, hence we cannot give a clear explanation either for the differences between East and West Europe nor for the high mortality observed in our current case series. However, it has long been reported by key opinion leaders of intensive care medicine in the region, that although we are more than 3 decades after the changing of the socialist system, several fundamental issues are still to be solved (31, 32). The most burning is the lack of human resources, including ICU nurses and doctors alike. Although our study did not focus on COVID-19 mortality in general, we cannot exclude that in the overall high ICU mortality, the low number of specialised ICU nurses and doctors and other logistic and organisational factors played a role. Unfortunately, we cannot refer to published data, but during the pandemic in our ICU, the specialised patient-to-nurse ratio often increased above 4:1. This is of utmost importance, as it has been shown by several studies that nurse/patient ratio has an exponential effect on mortality (33–35). In fact, if the patient-to-nurse ratio increases from 1:1 to >2.5:1 per shift, the adjusted risk ratio “shifts, with at least one death” increases from 1 to 3.5 (95% CI: 1.3–9.1) (31). In this region of Europe, we must take this opportunity to learn from the lessons of the pandemic that state-of-the-art equipment and treatment strategies, such as CytoSorb, cannot make a difference if the human resources do not match the international/European standards.

**Limitations**

Our study has many more limitations than strengths. It is a retrospective, single centre, small sample size case series without a control group. However, there are very few studies in general available on this topic. Furthermore, our results are not negative as far as the treatment’s immediate effects are concerned. Regarding long term outcomes, in comparison to international results, ours cannot be compared for the reasons detailed above. We could not present data on IL-6, and several other parameters.

**Conclusions**

In this small, single centre cohort we present the results of COVID-19 patients treated with hemoadsorption during their life-threatening critical illness. The treatment was well-tolerated and there was a tendency toward improvement in both vasopressor need and oxygenation during the course of hemoadsorption. These observations render the need for prospective randomised trials.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of Fejér County St. György University Teaching Hospital, Székesfehérvár, Hungary (No: 18/2021.05.11). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

ZM: conceptualisation, supervision, project administration, and funding acquisition. MR and MV: methodology. MV and BH: software. KO and MR: validation. AV and DB: formal analysis. MV: investigation, resources, and data curation. TL, MR, MV, and KO: writing—original draft preparation. ZM, LB, and ÁS: writing—review and editing. BH: visualisation. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

The article was funded by the project titled GINOP-2.3.2-15-2016-00048–STAY ALIVE is co-financed by the European Union (European Regional Development Fund) within the frame-work of Program Széchenyi 2020, Human Resources Development Operational Program Grant, Grant.
ACKNOWLEDGMENTS

Authors would like to thank Harriet Adamson for English language editing and Dr. Peter Recknagel for proofreading the manuscript.

REFERENCES

1. ICNARC. Reports. Available online at: https://www.icnarc.org/our-audit/audits/cmp/reports (accessed June 1, 2021).
2. John Hopkins University of Medicine Coronavirus Resource Center. Mortality Analyses. Available online at: https://coronavirus.jhu.edu/data/mortality (accessed June 2, 2021).
3. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. (2020) 71:762–8. doi: 10.1093/cid/ciaa248
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 46:846–8. doi: 10.1007/s00134-020-05991-x
6. Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE. (2017) 12:e0187015. doi: 10.1371/journal.pone.0187015
7. Hawchar F, László I, Oveges N, Tráty D, Ondrik Z, Molnár Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. (2019) 49:172–8. doi: 10.1016/j.jcrc.2018.11.003
8. Brouwer WAO, Duran S, Kuipper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. (2019) 23:317. doi: 10.1186/s13054-019-2588-1
9. KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. (2012) 2 (Suppl):1–138. doi: 10.1038/suppl.2012.1
10. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell-E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. (2012) 307:2526–33. doi: 10.1001/jama.2012.5696
11. Khwaaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. (2012) 120:c179–84. doi: 10.1159/000339789
12. Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makwah AM. Cytokine storm in COVID-19 patients, its impact on organs and potential treatment by QTY code-designed detergent-free chemokine receptors. Mediators Inflamm. (2020) 2020:8198963. doi: 10.1155/2020/8198963
13. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. (2020) 12:e12421. doi: 10.15252/emmm.202012421
14. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. (2020) 324:1565–7. doi: 10.1001/jama.2020.17052
15. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. (2020) 8:1233–44. doi: 10.1016/s2213-2600(20)30404-5
16. Rodríguez A, Ruiz-Botella M, Martín-Loeches I, Jimenez Herrera M, Solé-Violan J, Gómez J, et al. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit Care. (2021) 25:63. doi: 10.1186/s13054-021-03487-8
17. Rieder M, Wengenmayer T, Staudacher D, Duereschmid M, Supady A. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care. (2020) 24:435. doi: 10.1186/s13054-020-03130-y
18. Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med. (2021) 9:755–62. doi: 10.1016/s2213-2600(21)00177-6
19. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. (2020) 11:1708. doi: 10.3389/fimmu.2020.01708
20. Boss K, Jahn M, Wendt D, Haidari Z, Demircioğlu E, Thielmann M, et al. Extracorporeal cytokine adsorption: significant reduction of catecholamine requirement in patients with AKI and septic shock after cardiac surgery. PLoS ONE. (2021) 16:e0246299. doi: 10.1371/journal.pone.0246299
21. Poli EC, Alberio L, Buer-Der riots A, Marucci C, Roumy A, Kirsch M, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care. (2019) 23:108. doi: 10.1186/s13054-019-2399-4
22. Alharthy A, Faqhi F, Memish ZA, Balharmar A, Nasim N, Shahzad A, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series. Artif Organs. (2021) 45:E101–12. doi: 10.1111/aor.13864
23. Kogelmann K, Jaracz D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit. Care. (2017) 21:74. doi: 10.1186/s13054-017-1662-9
24. Rampino T, Gregorini M, Ferrari F, Patonneri EF, Grignano MA, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif. (2021) 50:566–71. doi: 10.1159/000511725
25. Lebreton G, Dormagh K, Quentin P, Combes A, Gorochov G, Schmidt M. Longitudinal cytokine profiling in patients with severe COVID-19 on extracorporeal membrane oxygenation and hemadsorption. Am J Respir Crit Care Med. (2021) 203:1433–5. doi: 10.1164/rccm.202011-4140LE
26. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. (2020) 370:m3339. doi: 10.1136/bmj.m3339
27. Villani L, Mackee M, Cascini E, Ricciardi W, Bocci S. Comparison of deaths rates for COVID-19 across Europe during the first wave of the COVID-19 pandemic. Front Public Health. (2020) 8:620416. doi: 10.3389/fpubh.2020.620416
28. Comparisons of All-Cause Mortality Between European Countries and Regions. (2020). Available online at: https://www.euro.who.int/en/960
29. James N, Menzies M, Radchenko P. COVID-19 second wave mortality in Europe and the United States. Chaos. (2021) 31:031105. doi: 10.1063/5.0041569
30. Daily New Confirmed COVID-19 Deaths Per Million People. Available online at: https://ourworldindata.org/covid-deaths (accessed June 6, 2021).
31. Molnár Z. SepsEast: bridging between east and west. J Crit Care. (2017) 40:323. doi: 10.1016/j.jcrc.2017.06.006
32. Lainscak M, Sustic A, Benes J, Czuczwar M, Jankovic R, Kirov M, et al. SepsEast and COVID-19: time to make a difference. Sigan Vitae. (2020) 161:4–10. doi: 10.22514/sv.2020.160001
33. Chaudhry R, Dranitsaris G, Mubashir T, Bartoszko J, Riazi S. A country level analysis measuring the impact of government actions,
country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine. (2020) 25:100464. doi: 10.1016/j.eclinm.2020.100464

34. Neuraz A, Guérin C, Payet C, Polazzi S, Aubrun F, Dailler F, et al. Patient mortality is associated with staff resources and workload in the ICU: a multicenter observational study. Crit Care Med. (2015) 43:1587–94. doi: 10.1097/CCM.0000000000001015

35. Lucchini A, Giani M, Elli S, Villa S, Rona R, Foti G. Nursing activities score is increased in COVID-19 patients. Intensive Crit Care Nurs. (2020) 59:102876. doi: 10.1016%2Fj.iccn.2020.102876

Conflict of Interest: ZM has received lecture honoraria form PULSION Medical, Germany (member of the Getinge Group), ThermoFisher Scientific and Biostest, Germany and he is a senior medical director at CytoSorbents Europe, Berlin, Germany. DB is employed by CytoSorbents Europe, Berlin, Germany; AV holds a contract as an external consultant with CytoSorbents Europe, Berlin, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Virág, Rottler, Ocskay, Leiner, Horváth, Blanco, Vasquez, Buci, Sárkány and Molnár. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.